摘要
目的观察拜复乐（莫西沙星）的临床疗效及安全性。方法以舒普深为对照,采用双盲、随机、对照的方法将符合入选条件的患者172例,随机分为试药组与对照组各86例。试药组给予拜复乐0.4g静脉滴注1次/天;对照组给予舒普深2g静脉滴注1次/8小时,疗程均为7-14天。结果试药组临床有效率为91%,细菌清除率为95%,不良反应发生率为7%;对照组临床有效率为92%,细菌清除率为93%,不良反应发生率为6%。经统计学处理两组各参数均无显著性差异（P〉0.05）。体外抗菌作用结果显示拜复乐抑菌效果显著。结论拜复乐用于治疗多种细菌感染性疾病,特别是耐药菌株引起的感染临床疗效确凿且不良反应轻微,其每日单次给药、依从性好,是一种安全、高效、方便的抗菌药物。
Objective To evaluate the efficacy and safety of moxifloxacina in treatment of bacterial infections.Methods 172 patients with bacterial infections were recruited and randomized divided to two groups.One group was treated with 0.4 g moxifloxacina intravenous injection one per day and another group with 4 g sulbactam/cetopazone dissolved in 100 ml 0.9% sodium chloride,one per 8 hours.Results The effective rate,bacterial clearance rate and incidence of side effect for moxifloxacina were 91%,95% and 7%;and for sulbactam/cetopazone were 92%,93% and 6% respectively.And there were no obviously difference between two groups.Conclusion Moxifloxacina is as safe and effective as sulbactam/cetopazone in treatment of infections.
出处
《西部医学》
2010年第6期1014-1016,共3页
Medical Journal of West China
关键词
拜复乐
舒普深
细菌感染性疾病
临床疗效
随机对照
Moxifloxacina
Sulbactam/cetopazone
Bacterial infections disease
Clinical efficiency
Random control
